IVF Failure: Common Causes and What They Mean for Next Steps

Medically reviewed on 26 August 2026 - Dr. Senai Aksoy
Calm woman at a cool blue-hour balcony looking over a pale city skyline — editorial still on reviewing a failed IVF cycle

Key Takeaways

IVF failure usually reflects a combination of embryo biology, age-related egg quality, sperm factors, uterine receptivity, and natural biological probability—rarely a single preventable mistake. The most constructive next step is a structured cycle review to decide whether to repeat the protocol, make targeted adjustments, or pursue further evaluation.

Key evidence: ASRM — Fertility evaluation of infertile women (2021) ESHRE — Good practice recommendations on recurrent implantation failure (2023) ASRM — Recurrent implantation failure: committee opinion (2026)

Receiving a negative pregnancy test after IVF can make one question crowd out all the others: why did this happen, and what does it mean for the future?

A useful review starts by identifying the stage at which the cycle stopped. The ovaries may have responded less than expected, fertilisation may have been low, embryos may have stopped developing, an embryo may not have implanted, or an early pregnancy may not have continued. These outcomes do not all have the same causes or the same next steps.

The aim is not to assign blame. It is to ask what this particular cycle actually showed, what remains uncertain, and whether anything specific needs to change.

Embryo Factors and Chromosomal Competence

Short answer: Embryo development and chromosomal competence are major determinants of whether implantation can begin and continue.

Age-related aneuploidy—an abnormal number of chromosomes—is considered a principal cause of implantation failure. An embryo can look excellent under the microscope and still have a chromosomal problem that morphology alone cannot detect. The ASRM committee opinion on recurrent implantation failure places age-related aneuploidy at the centre of this assessment.

The reverse is also important: a lower morphological grade does not prove that an embryo is chromosomally abnormal. Grading helps the laboratory choose between available embryos; it is not a genetic diagnosis or a promise of outcome. PGT-A may answer a different question in selected patients, but ASRM does not support it as a routine screening test for everyone having IVF.

Maternal Age and Ovarian Reserve

Short answer: Female age is strongly related to embryo aneuploidy and IVF prognosis, while ovarian reserve tests mainly estimate likely egg yield.

As age increases, the proportion of aneuploid embryos generally rises. This changes the probability attached to each cycle, but it does not provide an individual verdict.

The distinction matters. The ASRM opinion on fertility evaluation explains that AMH and antral follicle count are useful for anticipating ovarian response, but are poor independent predictors of reproductive potential. They should be read alongside age, treatment history and the details of the cycle.

Sperm Quality and Fertilisation Dynamics

Short answer: A cycle with unexpectedly low fertilisation or poor embryo development should include a review of the semen findings and the fertilisation process.

Semen concentration, motility and morphology are part of the couple’s evaluation. They do not, on their own, explain every arrest in embryo development. Laboratory factors, egg factors and sperm factors may overlap, so the cycle record needs to be reviewed as a whole.

Further male evaluation may be appropriate when the history, semen analysis or fertilisation pattern provides a reason. It should not automatically become a long list of add-on tests. The ASRM committee opinion on recurrent implantation failure finds insufficient evidence to recommend sperm DNA fragmentation testing routinely for recurrent implantation failure.

Uterine Receptivity and the Cavity Environment

Short answer: Uterine or tubal findings can matter, but one failed transfer does not automatically justify hysteroscopy, biopsy or a broad receptivity work-up.

Findings that may change management include:

Whether the cavity needs reassessment depends on previous imaging, symptoms, lining development and the number and type of failed transfers. For practical details, read our guide to endometrial thickness before embryo transfer.

The ESHRE good practice recommendations individualise the point at which repeated failure should prompt further investigation. The newer ASRM opinion notes that recurrent implantation failure is generally considered only after several good-quality blastocyst transfers, not after one unsuccessful transfer.

Biological Probability and Implantation Limits

Short answer: A single failed embryo transfer does not prove the presence of an undiscovered disease or an incorrect protocol.

Human reproduction is probabilistic. Even a euploid embryo can fail to implant, and a single outcome cannot show whether the explanation was embryo biology, the uterine environment or chance. The ASRM definition therefore uses an estimated cumulative probability across several good-quality blastocyst transfers rather than labelling one transfer as recurrent implantation failure.

After genuinely recurrent failure, a focused assessment may be reasonable. A 2024 review by Kuroda discusses possible tests after euploid embryo transfer failure, but it is a narrative review rather than a universal protocol. Decisions should be checked against current guidelines and the patient’s findings.

Practical Next Steps: What Changes After a Failed Cycle?

Short answer: The next step should follow the stage of failure and the evidence already available; sometimes the right decision is a targeted change, and sometimes it is another attempt without a broad new work-up.

Depending on where the cycle encountered difficulty, your fertility specialist may recommend:

The review should end with a short list: what was learned, what will change, what will stay the same, and why. Our guide to what to review after an unsuccessful IVF cycle walks through that conversation in more detail.

FAQ

Does one failed IVF cycle mean treatment is unlikely to work?

No. One result does not define the prognosis. Future chances depend on age, ovarian response, embryo development, transfer history and any findings that can reasonably be addressed.

Is IVF failure usually caused by a single mistake?

No. Implantation relies on a complex interplay between embryo genetics, endometrial receptivity, maternal age, sperm competence, and biological probability. It is rarely attributable to an isolated error.

When does failure justify extensive additional testing?

Broader investigation becomes more reasonable after the number of failed good-quality blastocyst transfers reaches an age- and embryo-specific threshold, or when symptoms, imaging or laboratory findings point to a particular problem. Recurrent pregnancy loss is a separate clinical pathway.

Does an unsuccessful cycle indicate an immune system disorder?

No. Current guidelines do not support routine immune testing or routine immunological therapies after implantation failure because evidence that they improve live birth is insufficient. For further reading, see immunological treatments and IVF implantation failure.

Should everything be changed before the next attempt?

No. If the cycle record does not identify a correctable problem, repeating a well-run protocol may be more reasonable than adding multiple unproven tests or treatments.

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

The content has been created by Dr. Senai Aksoy and medically approved.